



Phillip P. Duncan	Content Reviewer— Other Organization Expert	Heart Care For You Cardiac Health Management Network, P.C.—Medical Director	None	None	None	None	None	None
Howard J. Eisen	Content Reviewer— AHA	Drexel University College of Medicine—Chief, Division of Cardiology	None	None	None	None	None	None
Gregg C. Fonarow	Content Reviewer— 2017 Heart Failure ECDP Writing Committee	UCLA—Co-Chief, Division of Cardiology	<ul style="list-style-type: none"> <li>• Abbott*</li> <li>• Amgen</li> <li>• Janssen</li> <li>• Medtronic</li> <li>• Novartis*</li> </ul>	None	None	<ul style="list-style-type: none"> <li>• Medtronic</li> <li>• NHLBI*</li> <li>• NIH/NIAID*</li> <li>• Novartis*</li> </ul>	<ul style="list-style-type: none"> <li>• ACC†</li> <li>• AHA†</li> <li>• AMA†</li> </ul>	None
Nasrien E. Ibrahim	Content Reviewer— 2017 Heart Failure ECDP Writing Committee	Massachusetts General Hospital—Assistant in Medicine; Harvard Medical School—Assistant Professor of Medicine, Harvard Medical School	None	None	None	None	None	None
James L. Januzzi, Jr.	Content Reviewer— 2017 Heart Failure ECDP Writing Committee	Massachusetts General Hospital—Director, Dennis and Marilyn Barry Fellowship in Cardiology Research Cardiology Division; Harvard Medical School—Hutter Family Professor of Medicine	<ul style="list-style-type: none"> <li>• Abbott*</li> <li>• Novartis*</li> <li>• Phillips*</li> <li>• Roche Diagnostics*</li> </ul>	None	None	<ul style="list-style-type: none"> <li>• AbbVie (DSMB)*</li> <li>• Amgen (DSMB)*</li> <li>• Bayer (DSMB)*</li> <li>• Boehringer Ingelheim (DSMB)*</li> <li>• Cleveland Heart Labs*</li> <li>• Janssen (DSMB)*</li> <li>• Novartis (DSMB)*</li> <li>• Pfizer (DSMB)*</li> <li>• Prevensio*</li> <li>• Roche Diagnostics*</li> <li>• Siemens*</li> </ul>	None	None
Mariell Jessup	Content Reviewer— 2017 Heart Failure ECDP Writing Committee	American Heart Association—Science and Medical Officer	None	None	None	None	<ul style="list-style-type: none"> <li>• AHA*</li> </ul>	None
Corrine Jurgens	Content Reviewer— Other Organization Expert	Stony Brook University School of Nursing—	None	None	None	None	<ul style="list-style-type: none"> <li>• Heart Failure Society of America†</li> </ul>	None

		Associate Professor, Emeritus						
Frederick A. Masoudi	Content Reviewer—2017 Heart Failure ECDP Writing Committee	University of Colorado Anschutz Medical Campus—Professor of Medicine	• UpToDate	None	None	• ACC* • John A. Hartford Foundation*	• ABIM • ACC NCDR* • Massachusetts Medical Society	None
Gurusher S. Panjra	Content Reviewer—Heart Failure Council Chair	George Washington University—Director, Heart Failure and Mechanical Support Program	None	None	None	None	None	None
J. Herbert Patterson	Content Reviewer—Other Organization Expert	University of North Carolina Eshelman School of Pharmacy—Professor of Pharmacy and Executive Vice Chair, Division of Pharmacotherapy and Experimental Therapeutics; Research Professor of Medicine	• Novartis*	None	None	• Amgen† • Boehringer Ingelheim† • Merck† • Novartis† • Otsuka America†	None	None
Andrea L. Price	Content Reviewer—Solution Set Oversight Committee	Indiana University Health—Director, Quality Databases	None	None	None	• ACC Accreditation Foundation Board*	None	None
Scott M. Silvers	Content Reviewer—ACEP	Mayo Clinic School of Medicine—Chair Emeritus, Department of Emergency Medicine; Associate Professor of Emergency Medicine	None	None	None	• Janssen Pharmaceuticals†	None	None
Randall C. Starling	Content Reviewer—Other Organization Expert	Cleveland Clinic—Professor of Medicine; President Heart Failure Society of America, Kaufman Center for Heart Failure, Heart and Vascular Institute	• Medtronic • Novartis	None	None	• Abbott† • Cardiac Dimensions† • Medtronic • NIH* • Novartis†	• Amgen‡ • Corvia Medical‡ • Novartis‡	None
Mary Norine Walsh	Content Reviewer—ACC Expert and Forum Attendee	St. Vincent Heart Center—Medical Director, Heart Failure and Cardiac Transplantation; American	None	None	None	None	• NHLBI‡ • Thoratec‡	None

		College of Cardiology— Immediate Past President						
Alan G. Wasserman	Content Reviewer— 2017 Heart Failure ECDP Writing Committee	The George Washington School of Medicine— Eugene Meyer Professor; Chairman, Department of Medicine	None	None	None	None	• Departmental and University Endowments*	None
David E. Winchester	Content Reviewer— Solution Set Oversight Committee	University of Florida College of Medicine (UFCOM)—Associate Professor of Medicine; Malcom Randall VAMC— Staff Cardiologist; Assistant Cardiology Fellowship Program Director, Quality and Research; Co-Director, Advanced Fellowship for Cardiovascular Imaging; Co-Director, University of Florida (UF) Health Cardiac Imaging Group	None	None	None	• NHLBI†	• Alachua County Medical Society Board of Directors†	• Plaintiff, delay in care of CAD, 2018 • Defendant, delay in care of MI, 2018 • Defendant, missed MI, 2018
Mark J. Zucker	Content Reviewer— ACC Expert	Newark Beth Israel Medical Center—Director, Cardiothoracic Transplantation Programs; Rutgers University, New Jersey Medical School— Clinical Professor of Medicine	None	None	None	None	• Amgen‡ • Mesoblast‡ • Pfizer‡ • St. Jude‡	None

This table represents all relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of  $\geq 5\%$  of the voting stock or share of the business entity, or ownership of  $\geq \$5,000$  of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to <http://www.acc.org/guidelines/about-guidelines-and-clinicaldocuments/relationships-with-industry-policy> for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees.

\* Significant relationship.

† No financial benefit.

‡ Relationship with this company is limited to enrolling patients in clinical trials. This disclosure was entered under the Clinical Trial Enroller category in the ACC's disclosure system. To appear in this category, the author acknowledges that there is no direct or institutional relationship with the trial sponsor as defined in the ACC/AHA Disclosure Policy for Writing Committees.

AANP=The American Association of Nurse Practitioners; ABIM=American Board of Internal Medicine; ACC=American College of Cardiology; ACEP=American College of Emergency Physicians; AHA=American Heart Association; AMA=American Medical Association; CMS=The Centers for Medicare & Medicaid Services; DCRI=Duke Clinical Research Institute; DSMB=Data Safety Monitoring Board; ECDP=Expert Consensus Decision Pathway; FDA=Food and Drug Administration; MedCAC=Medicare Evidence Development & Coverage Advisory Committee; NCDR=National Cardiovascular Data Registry; NIAID=National Institute of Allergy and Infectious Diseases; NHLBI= National Heart, Lung, and Blood Institute; NIH=National Institutes of Health; PCORI= Patient-Centered Outcomes Research Institute; SCAI=Society for Cardiac Angiography and Interventions; UCLA=University of California Los Angeles; VAMC=Veterans Administration Medical Center.